Johnson & Johnson's Prostate Cancer Pill Just Posted a 75% Response Rate — Why JNJ Is Monday's Stock to Watch

Johnson & Johnson (NYSE: JNJ) announced on Sunday, October 25, 2026, that its experimental once-daily prostate cancer pill JNJ-6143 produced a confirmed complete or partial tumor response in 75% of patients with measurable disease in a Phase 1 study — 12 out of 16 patients — in men whose advanced cancer had already progressed through a median of four prior therapies. The data, presented at the ESMO Congress 2026 in Madrid, make JNJ one of the first stocks to watch when U.S. markets reopen on Monday.

What happened

Johnson & Johnson reported Phase 1 results for JNJ-6143, formerly known as HLD-0915, an investigational oral drug for metastatic androgen pathway modulation-resistant prostate cancer — also called metastatic castration-resistant prostate cancer, or mCRPC. These are patients whose disease keeps progressing despite hormone-pathway drugs, and who in this study had also already received chemotherapy and PSMA-targeted radioligand therapy.

At the 50 mg once-daily dose, the numbers were striking for such a heavily pre-treated group. Among 38 patients receiving that dose, 77% achieved a confirmed reduction in prostate-specific antigen (PSA) of at least 50%, and 48% saw their PSA fall by at least 90%. Among patients whose tumors could be measured on imaging, 75% had a confirmed complete or partial response under RECIST criteria. At the time of the analysis, 71% of patients on the 50 mg dose were still on treatment, with a median follow-up of 5.6 months.

On safety, the company said most treatment-related side effects were mild to moderate. The most common were elevated cholesterol (18%), nausea (16%) and elevated triglycerides (16%). Four patients (11%) interrupted their dose, one reduced it, and one discontinued treatment because of side effects.

Why this is blowing up

Three things are driving the attention. First, the setting: median overall survival for this type of resistant metastatic prostate cancer is roughly two to three years, so deep responses after four prior lines of therapy stand out. Second, the mechanism is genuinely new. JNJ-6143 is the first drug from Johnson & Johnson's RIPTAC platform to reach clinical studies. Instead of simply blocking the androgen receptor, a RIPTAC molecule creates a targeted dual-protein lock between BRD4 — a protein cancer cells need to survive — and the androgen receptor, highly expressed in prostate cancer cells. That lock is designed to disrupt the cancer cell and trigger its death.

Third, the timing matters for the stock. JNJ shares closed Friday at $263.81, down 1.42%, before the Sunday release, so Monday is the first U.S. session that can price the news in. Weekend trading in Europe was muted — EUR 235.38 on Lang & Schwarz on Sunday, about 0.14% above Friday's Xetra close. Analysts cited in coverage of the release rate JNJ a Moderate Buy on average, with an average price target of $288.71, roughly 9% above Friday's close. This post reports what happened and how markets reacted; it is not a recommendation to buy, sell or hold any security.

Key facts

• Response rate: 75% (12 of 16) confirmed complete or partial responses in patients with measurable disease.
• PSA results at 50 mg: 77% of 38 patients achieved at least a 50% PSA reduction; 48% achieved at least a 90% reduction.
• Patient group: Advanced prostate cancer after a median of four prior therapies, including chemotherapy and PSMA-targeted radioligand therapy.
• Dose moving forward: The 50 mg once-daily dose was selected for continued development, including a Phase 2 study (NCT07832292). The Phase 1 study is NCT06800313.
• Where it was presented: Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2026, abstract #2216O.
• Where the drug came from: Johnson & Johnson acquired Halda Therapeutics in December 2025, adding JNJ-6143 and the RIPTAC platform to its oncology portfolio.

Investigator Professor Johann de Bono of the Institute of Cancer Research in London called the results encouraging, citing meaningful anti-tumor activity after multiple prior therapies. J&J oncology head Yusri Elsayed said the data support further development of JNJ-6143 and broader exploration of RIPTAC across other cancers.

What's next

The immediate test is Monday's market reaction, but the bigger story is developmental. Phase 1 data in 16 measurable-disease patients is early evidence, not proof — the 50 mg dose now advances into Phase 2, where larger numbers will show whether the response rate holds and how durable responses are. Investors will also watch whether RIPTAC can become a platform rather than a single drug. For now, JNJ-6143 has given a difficult-to-treat patient group, and the market, a concrete reason to pay attention.

FAQ

What is JNJ-6143?
JNJ-6143 is Johnson & Johnson's investigational once-daily oral prostate cancer drug, the first candidate from its RIPTAC platform. It works by locking together the BRD4 and androgen receptor proteins inside cancer cells to disrupt them and trigger cell death.

How well did JNJ-6143 work in the Phase 1 study?
Among patients with measurable disease, 75% (12 of 16) had a confirmed complete or partial tumor response. At the 50 mg dose, 77% of patients achieved at least a 50% PSA reduction and 48% achieved at least a 90% reduction.

When did Johnson & Johnson announce the JNJ-6143 results?
The company announced the results on Sunday, October 25, 2026, after presenting them at the ESMO Congress 2026 in Madrid. JNJ shares had closed Friday at $263.81, down 1.42%, so Monday, October 26 is the first U.S. session to react.

What happens next for JNJ-6143?
The 50 mg once-daily dose advances into further development, including a Phase 2 study in metastatic prostate cancer (NCT07832292). The drug remains investigational and is not approved.

Sources: Johnson & Johnson press release, October 25, 2026; Morningstar / PR Newswire; TipRanks / TheFly; TalkMarkets. This article is news reporting only and is not financial advice.